Saturday, 23 April 2011

AAN P05.032 - neuroprotective potential of BG12

AAN = 63rd American Academy of Neurology meeting in Hawaii

Racke et al. Neuroprotective Potential of Fumaric Acid Esters in a Model of Multiple Sclerosis. P05.032.

BG12 = Fumaric Acid Esters or dimethyl fumarate (DMF)

Pretreatment of mice with DMF reduced inflammatory lesion size by 30% and behavioral performance or recovery by 50%.

"In view of the positive phase 3 results and the mode of action of BG12 these results are very exciting. I still believe that BG12 will be an ideal add-on drug to existing anti-inflammatory DMDs."


COI: I sit on the steering committee for the BG12 phase 3 programme and receive consultancy fees for this role.

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.